Os Therapies Completes $6 Million Series A Funding Round
04/20/21, 12:53 PM
Location
new yorkMoney raised
$6 million
Industry
biotechnology
Round Type
series a
OS Therapies, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat and cure Osteosarcoma (OS) and other deadly cancers in kids and adults including ovarian, esophageal, endometrial and lung cancers, today announced the closing of a $6 million Series A round of funding.
Company Info
Location
new york, new york, united states
Additional Info
OS Therapies is a clinical stage research company focusing on therapeutic treatments for Osteosarcoma, Breast Cancer and other solid tumors with two platform technologies: OST-HER2 to prevent metastasis and OST-tADC to debulk solid tumors.